clinical goldenseal - metformin study CSV JSON

In Vivo Interaction Study

clinical goldenseal - metformin study

Decreased systemic exposure was detected.

metformin 1503297

goldenseal root extract

  • MATE1 (SLC47A1)
  • MATE2-K (SLC47A2)
  • OCT1 (SLC22A1)
  • OCT2 (SLC22A2)

Results

Sample Compound measured Value Measurement Study sequence Additional information N replicates

Experimental Conditions

Probe cocktail study
Fixed-sequence

Population

Healthy volunteers

16

8 male and 8 female (non-lactating women )

Pharmacokinetic (PK) Sampling Information

24, 48, 72, and 96 hours after cocktail administration

Drug or Natural Product Administration

Object Administration — metformin

Oral

Furosemide (10 mg/mL solution; West-ward Pharmaceuticals Corp., Eatontown, NJ), metformin (500 mg/5 mL solution; Ranbaxy Pharmaceuticals, Inc., Jacksonville, FL), rosuvastatin (10 mg tablet; Camber Pharmaceuticals Inc., Piscataway, NJ), and midazolam (2 mg/mL syrup; West-ward Pharmaceuticals Corp.)

1 mg furosemide, 50 mg metformin, 10 mg rosuvastatin, and 2.5 mg midazolam

single dose

once

Precipitant Administration — goldenseal root extract

Oral

capsule

3 g

1 g every 4 hours

3 times

Natural Product Characteristics

Now Foods, Bloomingdale, IL

2019